Connect with us
European Gaming Congress 2024

Fintech PR

Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs

Published

on

health-and-wellness-industry-embraces-surge-in-demand-for-weight-loss-drugs

USA News Group News Commentary
Issued on behalf of PlantX Life Inc.

VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ — USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it’s no wonder why analysts at SNS Insider are projecting the Weight Loss Drugs Market to grow at a whopping 43.73% CAGR through 2032. It’s one of the fastest growing markets in pharmaceuticals, with nearly one in four employers saying they’re either somewhat or very likely to begin covering the cost of anti-obesity medications within the next year. Health and wellness companies are responding in kind, with recent market developments coming from: PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), Novo Nordisk A/S (NYSE: NVO), Eli Lilly and Company (NYSE: LLY), Viking Therapeutics, Inc. (NASDAQ: VKTX), and Roche Holding AG (OTCQX: RHHBY).

The article continued: According to Morgan Stanley, the global market for blockbuster obesity drugs could increase by more than 15x over the next five years, as their benefits expand beyond weight loss, with expected implications for consumer goods and longevity. With big pharma players entering the race, new weight loss drugs could be developed even faster.

PlantX Life Inc. Announces Joint Venture with LIV3 to Launch SugarShield Supplement Addressing the USD 5.24 Billion Weight Loss Management Supplement Market

PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF), a pioneer in building strong communities and operating innovative experiential online and in-store platforms that make it easier for individuals to lead happier and healthier lives, today announced a joint venture with LIV3, founded by Christopher Mearns, to launch their SugarShield supplement. Aimed at addressing the growing US$5.24 billion Weight Loss Management Supplement Market, PlantX will manage the design of SugarShield’s branding and packaging as part of the JV, while also developing a user-friendly e-commerce platform to support the supplement’s launch. PlantX Life will lead all marketing intitiatives, including utilizing its proprietary SEO strategies to build the brand’s presence, while Chris Mearns will oversee the product supply. Net profits from all sales will be shared equally, with a 50/50 split.

“As the weight loss supplement market continues to expand, driven by excitement around the popularity in products once designed for treating effects of type 2 diabetes, we at PlantX see this as an opportunity to offer a plant-based alternative without the synthetic properties,” said Lorne Rapkin, CEO of PlantX. “We believe Chris Mearns has developed what can be considered ‘nature’s Ozempic’ with SugarShield. We’re confident that the branding, packaging, and website we create will reflect the innovation and benefits of this product, making it stand out in the growing weight management market.”

The joint venture with PlantX will provide LIV3 with the resources to create a strong online presence for SugarShield. PlantX’s expertise in branding and digital platforms will help the supplement reach health-conscious consumers worldwide.

LIV3 suggests that SugarShield is designed to help users boost energy, curb cravings, and simplify weight management—all without the need for restrictive diets. After years of development, Christoper Mearns has created a formula that provides consumers with the health benefits typically associated with sugar-free diets, while fitting seamlessly into everyday lifestyles. According to Mearns, the supplement works by reducing uric acid, a key contributor to cellular stress, enabling users to improve their metabolic health.

“With LIV3’s SugarShield, consumers can detox from the negative effects of fructose without changing their diet,” said Christopher Mearns, founder of LIV3. “This supplement improves energy levels through enhanced mitochondrial function, supports glucose utilization, and increases insulin sensitivity, leading to weight loss and improved metabolic conditions. We’ve already begun designing the branding and packaging with the PlantX team, and we’re very excited about the upcoming launch. Simply put, our metabolic health was broken by daily fructose intake, and luteolin is the answer because it blocks the harmful effects of fructose.”

An integral part of this collaboration is Paul Gross, a long-time member of PlantX’s medical panel. Dr. Gross has played a crucial role in validating the medical science behind SugarShield, ensuring that the supplement’s formulation is both effective and grounded in scientific research. His expertise and support have been instrumental in building confidence in the potential benefits of SugarShield, allowing both PlantX and LIV3 to bring this innovative product to market with the assurance of its efficacy.

Advertisement

This joint venture aligns with PlantX’s ongoing commitment to expanding its plant-forward wellness offerings while tapping into the rapidly growing health and supplement sectors.

CONTINUED… Read this and more news for PlantX Life at:  https://usanewsgroup.com/2024/10/08/from-plants-to-plates-wellness-delivered/

In other industry developments and happenings in the market this week include:

Novo Nordisk A/S (NYSE: NVO), the company behind Ozempic, recently announced that its oral semaglutide (Rybelsus®) (the active ingredient in Ozempic and Wegovy) reduced the risk of major adverse cardiovascular events by 14% in adults with type 2 diabetes, according to the SOUL trial. The randomized, double-blinded study enrolled 9,650 participants with type 2 diabetes and cardiovascular or chronic kidney disease, with 49% also receiving SGLT2 inhibitors during the trial.

“We are pleased to see that the results from SOUL demonstrate that oral semaglutide reduces the risk of cardiovascular events and that the benefits of oral semaglutide come on top of standard of care,” said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. “Approximately one in three adults with type 2 diabetes also have cardiovascular disease; therefore, it is crucial to have therapies that can address both conditions.”

The trial met its primary objective by showing a 14% reduction in MACE for those treated with oral semaglutide compared to placebo. The primary endpoint, defined as the first occurrence of cardiovascular death, non-fatal heart attack, or non-fatal stroke, saw contributions from all three components, confirming oral semaglutide’s superior MACE reduction.

Eli Lilly and Company (NYSE: LLY), maker of Ozempic and Wegovy competitor drugs Mounjaro and Zepbound, recently said it had sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets. The new lawsuits against Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine of Nevada are the first to target copycat tirzepatide since the U.S. Food and Drug Administration (FDA) removed the drug from its short supply list earlier this month.

Lilly is bringing these actions to protect American consumers from direct patient safety risks,” said a Lilly spokesperson, adding that the defendants were making false claims regarding efficacy and safety, while also misleading consumers about the clinical data supporting those claims.

Earlier this year, Eli Lilly already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, which is also approved to treat type 2 diabetes under the brand name Mounjaro. Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages.

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced back in June that it had presented preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. The presentation highlighted the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide.

Advertisement

“The amylin receptor plays an important role in food intake and metabolic control, making it an attractive target for therapeutic intervention in obesity,” said Brian Lian, Ph.D., CEO of Viking.  “These data demonstrate the potent activity of a series of novel, internally developed, amylin and calcitonin dual agonists and represent an exciting expansion of our pipeline in obesity and metabolic diseases. This program provides Viking with additional opportunities to develop novel, differentiated therapies for obesity with potentially best-in-class profiles.”

Roche Holding AG (OTCQX: RHHBY), a Swiss-based global pharmaceutical leader, recently told investors that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than US$3.6 billion in annual sales. According to a presentation Roche gave, the revenue projection applies on aggregate to weekly injection CT-388—which is similar to Lilly’s Zepbound—and daily pill CT-996 as well as CT-868 against type 1 diabetes. In total, at least seven drugs in Roche’s development pipeline have peak sales potential of more than US$3.6 billion.

According to a report from Financial Times, Roche is planning to launch 20 medicines by the end of the decade, while cutting research costs for new drugs by a fifth.

“We want to make sure our engine works extremely efficiently,” said Thomas Schinecker, CEO of Roche, in the presentation that outlined a focus on oncology, haematology, neurology, cardiovascular and metabolic diseases, eye diseases and immune diseases. “The bar is high.”

Source: https://usanewsgroup.com/2024/10/08/from-plants-to-plates-wellness-delivered/

CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for PlantX Life Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of PlantX Life Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of PlantX Life Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of PlantX Life Inc. at any time without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, we currently own shares of PlantX Life Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/health-and-wellness-industry-embraces-surge-in-demand-for-weight-loss-drugs-302286062.html

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

DFC Expands Global Impact With Record-Breaking Investments in Fiscal Year 2024

Published

on

dfc-expands-global-impact-with-record-breaking-investments-in-fiscal-year-2024

Total annual commitments more than doubled since agency’s launch five years ago
Driving global development with more than 180 strategic transactions

WASHINGTON, Oct. 24, 2024 /PRNewswire/ — The U.S. International Development Finance Corporation today announced that it committed a record $12 billion in investments in Fiscal Year 2024 to projects that are improving lives and promoting economic growth across the developing world by expanding access to food, energy, healthcare, critical infrastructure, and financial services.

In Fiscal Year 2024, DFC tackled some of the world’s greatest challenges by supporting transactions in 44 countries, with a total portfolio spanning over 110 countries across Africa, the Middle East, Latin America, Europe, and the Indo-Pacific. DFC’s new commitments are expected to finance 450,000 smallholder farmers, generate 4,600GWh of renewable energy, improve healthcare for more than 11 million patients, and fuel growth for 380,000 micro, small, and medium-sized businesses.

“Fiscal Year 2024 was a remarkable year for DFC, both in terms of volume of investment and our impact on some of the world’s most pressing challenges. In just five years since its creation, DFC’s private-sector-led approach has established DFC as a pivotal instrument in U.S. foreign policy and a key player in the development finance space,” said DFC CEO Scott Nathan. “The new investments made this year will provide badly needed financing to entrepreneurs and businesses, driving economic growth and stability in the countries where we work. I’m proud of the hard work and accomplishments of the DFC team to support development and bolster U.S. national security.”

In Fiscal Year 2024, DFC committed to over 180 transactions. Activity included:

Invested where American values and interests intersect. DFC’s dual focus on global development and American national security helps ensure its investments benefit both the United States and the host countries.

  • In Angola, DFC’s board approved a loan of up to $553 million to the Lobito Atlantic Railway to support the upgrade and rehabilitation of more than 800 miles of rail and a mineral port to help ensure the reliable transport of minerals that are critical to the clean energy transition. In a related transaction, DFC also committed a $3.4 million technical assistance grant to Pensana to conduct feasibility studies to advance development of a rare earth mine and refining facility in the Lobito Corridor.
  • In Indonesia, an up to $126 million DFC loan to PT Medco Cahaya Geothermal will finance the development of approximately 31.4MW of geothermal power generation capacity in East Java.
  • In South Africa, a $50 million equity investment in TechMet will support the development of the Phalaborwa Rare Earths project, a rare earth element processing facility that will develop a more diverse, resilient, and sustainable critical mineral supply chain, drive the clean energy transition, and create economic opportunity for local communities.

Provided critical support to the people and businesses impacted by the war in Ukraine. DFC continued its support for Ukraine, committing more than $580 million to a wide range of sectors crucial to the country’s recovery and stability amid the conflict. This included one of its signature tools to address the most urgent Ukrainian economic needs and lay a foundation for long-term resilience: political risk insurance.

  • $10 million in political risk insurance will support the rebuilding of a water treatment and water filtration equipment manufacturing facility destroyed during Russia’s invasion.
  • $50 million in political risk insurance will support a reinsurance facility brokered by Aon and distributed by ARX to build a portfolio of war risk insurance policies for companies operating in Ukraine and to support ARX in expanding its war risk insurance offering in the country.
  • $150 million in political risk insurance will help maintain the country’s agriculture operations and alleviate food insecurity.

Strengthened global supply chains. DFC invested in infrastructure to bolster access to essential goods and services including food, energy, healthcare, technology, and critical minerals.

  • In South Africa, a €110 million DFC loan will help Aspen Pharmacare expand its capacity to deliver medicines, diabetes insulin, and pediatric vaccines, increasing local access to life-saving medicines and vaccines across Africa.
  • In Zambia, a $10 million loan to Seba Foods Zambia Ltd. will support the expansion of the company’s storage and production capacity and provide affordable, soy-based consumer food products, strengthening the food value chain in Zambia.
  • In Türkiye, a $350 million loan to Enerjisa Enerji Üretim A.Ş. will finance the development, construction, and operation of nine onshore wind power plants in Western Türkiye that are expected to generate approximately 2.51 terawatt-hours per year.

Advanced high-standard, transparent investing to achieve sustained impact. DFC adheres to the highest standards on worker rights and the environment and works to ensure its investments deliver a sustained positive impact.

  • In India, DFC committed a $10 million loan to Nepra Resource Management for construction of material recovery facilities for the recycling and sustainable disposal of material waste that will reduce waste in landfills.
  • Across Africa, a $250 million tier 2 capital loan to Africa Finance Corporation will strengthen the capital position of a key pan-African multilateral development finance institution to support its operating activities, including investment activities consisting of infrastructure projects critical to economic growth and development.
  • In the Western Hemisphere, a $50 million equity investment in PI Fund V (Ontario), L.P. will increase investments in Latin American infrastructure and address financing gaps to develop critical projects, with a primary focus on Brazil, Colombia, Peru, and Mexico.

Supported the world’s low-income countries and underserved communities. DFC focuses a majority of its transactions in low- and lower-middle-income countries and prioritizes investments that benefit women and other underserved populations.

  • In India, a $50 million loan to InCred Financial Services Ltd. will support lending to women and women-owned businesses using a technology-enabled lending approach designed to expand access to underserved entrepreneurs and individuals.
  • In the Dominican Republic, where nearly one quarter of the population lives below the poverty line, DFC committed $200 million in financing to Banco Popular Dominicano, S.A. to support lending to small businesses, with a focus on women entrepreneurs.
  • In the Philippines, DFC committed a $20 million loan to Lhoopa Singapore Pte. Ltd. that will support a digital platform focused on the development of affordable housing for low-income families throughout the country.

Learn more about DFC’s record-breaking year. 

The U.S. International Development Finance Corporation (DFC) partners with the private sector to finance solutions to the most critical challenges facing the developing world today. We invest across sectors including energy, healthcare, infrastructure, agriculture, and small business and financial services. DFC investments adhere to high standards and respect the environment, human rights, and worker rights.

Logo – https://mma.prnewswire.com/media/2514418/DFC_Horizontal_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/dfc-expands-global-impact-with-record-breaking-investments-in-fiscal-year-2024-302286349.html

Continue Reading

Fintech PR

H.I.G. WhiteHorse Europe Provides Financing to Altares

Published

on

hig.-whitehorse-europe-provides-financing-to-altares

LONDON, Oct. 24, 2024 /PRNewswire/ — H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital (“H.I.G.”), is pleased to announce that it has arranged a financing package for Altares (“Altares” or the “Group”).

Supported by Naxicap Partners since 2016, Altares is a leader in the business data and analytics market, offering its expertise to B2B customers across the entire data value chain in Finance Intelligence, Sales Intelligence, ESG, and Compliance.

H.I.G. WhiteHorse Europe acted as sole arranger and sole underwriter of a €93 million financing package, which will refinance Altares’ existing indebtedness and support its next stage of growth.

Luc Querton, President of Altares, said: “We strive to reveal growth opportunities for our clients, support them in managing credit risks, advise them on the ESG profiles of their third parties, and help ensure compliance with applicable regulations. This financing allows us to sustain our growth while continuing to deliver innovative technologies which meet our clients’ increasingly complex requirements across these four areas.”

Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said: “Altares benefits from a unique brand image and leadership position in the growing business data, digitalization, and analytics industry. The financing we provided reflects our confidence in the expansion strategy implemented by Altares’ management team, alongside Naxicap Partners.”

About Altares

A leader in business insights, Altares collects, structures, analyses and enhances B2B data to make them “smart” and powerful to facilitate decision-making by its customers. The Group offers its expertise across the entire data value chain in financial risk, compliance, sales and marketing, and master data management. Altares has an exclusive partnership in France, Benelux and North Africa with Dun & Bradstreet, the world’s leading global provider of business decisioning data and analytics for almost 200 years. This makes Altares the partner of choice for executives in all sectors offering them unprecedented access to database of over 550 million companies in more than 240 countries. For more information, visit altares.com.

About Naxicap Partners

As one of the top private equity firms in France, Naxicap Partners has €6.7 billion in assets under management. As a committed, responsible investor, Naxicap Partners builds solid, constructive partnerships with entrepreneurs so that their projects can succeed. The firm has 95 investment professionals spread across five offices in Paris, Lyon, Toulouse, Nantes, Frankfurt, and Zurich. For more information, visit naxicap.com/en.

About H.I.G. Capital

Advertisement

H.I.G. is a leading global alternative investment firm with $65 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, Dubai, and Hong Kong, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/value-added approach:

  • H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  • H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
  • H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
  • H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.

Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.

*Based on total capital raised by H.I.G. Capital and affiliates.

Contact:

Pascal Meysson
Head of H.I.G. WhiteHorse Europe
[email protected] 

Laurent Vaille
Principal
[email protected]

H.I.G. WhiteHorse Europe
10 Grosvenor Street
2nd Floor
London W1K 4QB
P +44 (0) 207 318 5700
hig.com

Logo – https://mma.prnewswire.com/media/2538962/HIG_WhiteHorse_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/hig-whitehorse-europe-provides-financing-to-altares-302286276.html

Continue Reading

Fintech

Xsolla significantly expands payment solutions in Cambodia and Indonesia to maximize game developers’ reach

Published

on

xsolla-significantly-expands-payment-solutions-in-cambodia-and-indonesia-to-maximize-game-developers’-reach

Xsolla, a global video game commerce company, is pleased to announce the expansion of its payment solutions in Cambodia and Indonesia, providing access to localized payment methods tailored to each region. This initiative aligns with Xsolla’s broader strategy to strengthen its presence across Southeast Asia (SEA) and support game developers in effectively monetizing and distributing their games in these rapidly growing markets.

In Cambodia, Xsolla introduces eight new payment methods, including Internet banking options and digital wallets, tailored to the preferences of Cambodian users. This strategic expansion covers up to 90% of the payments market, ensuring that nearly every player in Cambodia can pay using their preferred method. For example, Bakong KHQR, a QR code-based payment system, holds 45% of the market share, while Acleda Bank accounts for 15%. Supported by the country’s ongoing digital transformation, with digital payment transactions surging by 28.7%, these solutions, including Wing Money, Pi Pay, and others, will enable game developers to reach nearly 2 million gamers in Cambodia, facilitating seamless checkout experiences and boosting sales.

In Indonesia, Xsolla is introducing several new payment methods to help game developers tap into the country’s vast gaming market, with over 185 million gamers out of a 275 million-strong population. Approximately 80% of consumers in Indonesia are unbanked or underbanked. With smartphone penetration reaching up to 80%, Alternative Payment Methods (APMs) are the most preferred option in Indonesia. By integrating these APMs, Xsolla can cover up to 90% of the market. This includes E-wallets, which account for 39% of the market, Bank Transfers at 27%, Cards at 17%, and Cash at 11%. Popular platforms such as ShopeePay, Jenius, and Akulaku are among the new payment options, simplifying transactions for Indonesian gamers and boosting market reach for game developers in one of the fastest-growing digital markets globally.

“Xsolla’s commitment to empowering game developers to access new markets is central to our mission. By introducing localized payment methods in Cambodia and Indonesia, we provide our partners with the tools they need to succeed in these dynamic and rapidly growing gaming environments. This expansion is part of our ongoing efforts to support developers globally and help them overcome payment challenges,” said Chris Hewish, Chief Strategy Officer of Xsolla.

The gaming market in Cambodia is projected to reach $75.21 million by 2027, with mobile games accounting for 66% of the revenue in 2023. In Indonesia, digital transformation opens up significant opportunities for game developers, mainly through localized payment solutions that reduce friction and improve transaction success rates.

The post Xsolla significantly expands payment solutions in Cambodia and Indonesia to maximize game developers’ reach appeared first on HIPTHER Alerts.

Continue Reading

Trending